Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 13, 2022, by Harrow Health, Inc. (Harrow), a Delaware corporation. The filing details two material definitive agreements entered into in mid-December 2022 to raise capital: a registered direct offering of common stock and a public offering of senior notes. The company is headquartered in Nashville, Tennessee.
Key Financial Metrics and Capital Structure
The filing focuses on capital raising activities rather than operational performance metrics such as revenue or profit margins. Key financial figures disclosed include:
- Common Stock Offering: Sold 2,376,426 shares at $10.52 per share, generating gross proceeds of $25,000,002. The offering closed on December 16, 2022.
- Senior Notes Offering: Agreed to sell $35,000,000 in aggregate principal amount of 11.875% Senior Notes due 2027. An option exists for underwriters to purchase an additional $5,250,000 in notes.
- Management Participation: Company management and board members agreed to purchase an aggregate of $950,000 of the Senior Notes.
- Existing Debt: The company has 8.625% Senior Notes due 2026 (trading symbol HROWL) registered on the NASDAQ Global Market.
- Liquidity and Pro Forma: The filing references an Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2022, which incorporates the new equity and debt, the divestment of non-ophthalmology compounding revenue, and a committed Senior Secured Loan facility. Specific liquidity values are not provided in the text.
Material Changes and Strategic Actions
The primary material change is the significant increase in capitalization through the dual offering. Additionally, the pro forma financials reflect a strategic divestment of the company's non-ophthalmology related compounding revenue line and related intangible assets. The company also entered into a lock-up agreement where officers and directors agreed not to sell common stock for 90 days following the underwriting agreement.
Outlook, Risks, and Contingencies
The filing contains standard forward-looking statements regarding the intended use of proceeds and business performance, noting that actual results may differ due to risks and uncertainties. The Senior Notes offering was expected to close on or about December 20, 2022, subject to customary closing conditions. The company explicitly states it does not assume an obligation to update forward-looking statements. The pro forma balance sheet assumes the application of a Senior Secured Loan facility, indicating a broader refinancing or liquidity strategy beyond the immediate offerings.
Investor Verification Checklist
- Verify the final closing date and net proceeds of the Senior Notes offering, including whether the underwriters exercised the option to purchase additional notes.
- Review the Unaudited Pro Forma Condensed Consolidated Balance Sheet (Exhibit 99.2) to assess the impact of the new debt, equity, and asset divestment on the company's leverage and liquidity ratios.
- Confirm the terms and status of the committed Senior Secured Loan facility mentioned in the pro forma adjustments.
- Examine the specific use of proceeds disclosed in the press release (Exhibit 99.1) to understand management's capital allocation strategy.
- Monitor the 90-day lock-up period expiration for insider trading activity.